Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HFB301001 (OX40 agonist antibody) in advanced solid tumors
NCT05229601Phase 1Terminated
- Sponsor
- HiFiBiO Therapeutics
- Start
- Apr 2022
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of HFB3010 in soft tissue sarcoma (STS), renal cell carcinoma (RCC), uterine carcinosarcoma (UCS) and 3 more, sponsored by HiFiBiO Therapeutics. Primary endpoints: Adverse Events and Recommended Phase 2 Dose. Started Apr 2022; status: terminated.
02
Drugs
HFB3010
03
Conditions
soft tissue sarcoma (STS)renal cell carcinoma (RCC)uterine carcinosarcoma (UCS)hepatocellular carcinoma (HCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05229601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05229601.